...
首页> 外文期刊>Molecules >Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs
【24h】

Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs

机译:中草药mGluR1潜在负变构调节剂的虚拟筛选和分子动力学研究

获取原文
获取原文并翻译 | 示例

摘要

The metabotropic glutamate subtype 1 (mGluR1), a member of the metabotropic glutamate receptors, is a therapeutic target for neurological disorders. However, due to the lower subtype selectivity of mGluR1 orthosteric compounds, a new targeted strategy, known as allosteric modulators research, is needed for the treatment of mGluR1-related diseases. Recently, the structure of the seven-transmembrane domain (7TMD) of mGluR1 has been solved, which reveals the binding site of allosteric modulators and provides an opportunity for future subtype-selectivity drug design. In this study, a series of computer-aided drug design methods were utilized to discover potential mGluR1 negative allosteric modulators (NAMs). Pharmacophore models were constructed based on three different structure types of mGluR1 NAMs. After validation using the built-in parameters and test set, the optimal pharmacophore model of each structure type was selected and utilized as a query to screen the Traditional Chinese Medicine Database (TCMD). Then, three different hit lists of compounds were obtained. Molecular docking was used based on the latest crystal structure of mGluR1-7TMD to further filter these hits. As a compound with high QFIT and LibDock Score was preferred, a total of 30 compounds were retained. MD simulation was utilized to confirm the stability of potential compounds binding. From the computational results, thesinine-4'-Omicron-beta-D-glucoside, nigrolineaxanthone-P and nodakenin might exhibit negative allosteric moderating effects on mGluR1. This paper indicates the applicability of molecular simulation technologies for discovering potential natural mGluR1 NAMs from Chinese herbs.
机译:代谢型谷氨酸亚型1(mGluR1)是代谢型谷氨酸受体的成员,是神经系统疾病的治疗靶标。但是,由于mGluR1正构化合物的亚型选择性较低,因此需要一种新的靶向策略,即变构调节剂研究,来治疗与mGluR1相关的疾病。最近,mGluR1的七个跨膜结构域(7TMD)的结构已得到解决,这揭示了变构调节剂的结合位点,并为未来的亚型选择性药物设计提供了机会。在这项研究中,利用了一系列计算机辅助药物设计方法来发现潜在的mGluR1负变构调节剂(NAM)。基于mGluR1 NAM的三种不同结构类型构建了药理学模型。使用内置的参数和测试集进行验证后,选择每种结构类型的最佳药效团模型,并将其用作查询以筛选中药数据库(TCMD)。然后,获得了三个不同的化合物命中列表。基于mGluR1-7TMD的最新晶体结构,使用了分子对接来进一步过滤这些命中物。由于QFIT和LibDock得分高的化合物是优选的,因此总共保留了30种化合物。 MD模拟用于确认潜在化合物结合的稳定性。从计算结果来看,thesineine-4'-Omicron-beta-D-葡萄糖苷,nigrolineaxanthone-P和nodakenin可能对mGluR1表现出负的变构调节作用。本文指出了分子模拟技术在从中草药中发现潜在的天然mGluR1 NAM的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号